ArticleJournal of clinical and translational science2026
A point-based system to determine authorship eligibility in a large clinical trial: Insights from the ISCHEMIA trial's authorship nomination system.
Article in Journal of clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: In team science, invitation to writing groups can be subjective and secretive. Confronted with this challenge in the ISCHEMIA trial, with 320 participating sites, 4 coordinating centers, 6 core laboratories, and numerous committees, we adapted an existing model to develop a transparent, objective, and equitable method for determining authorship eligibility. Methods: We developed a scoring system based on site performance of tasks critical to trial success that meet the ICJME criteria for authorship. Sites were ranked according to points earned, and points required for potential authorship were communicated to all sites. Site investigators were surveyed for their manuscript topic preferences for writing groups. Beyond the point-based system, authorship positions were also reserved for trial contributors who were not site investigators. Results: To date, 50 original, peer-reviewed ISCHEMIA trial manuscripts have been published. In total, 208 authors from 33 countries participated in at least one publication. Of the 87 sites that randomized at least 15 participants over a mean of 5 years, 72% had authorship positions across published manuscripts. Surveys were sent to 334 site investigators and 27% responded. Among respondents, 61% indicated that ISCHEMIA was the first trial they had worked on with performance-based criteria for authorship invitation. Respondents agreed the system was transparent (81%), objective (83%), and equitable for early career researchers (70%) and underrepresented minorities in research (57%). Conclusions: ISCHEMIA employed a point-based authorship eligibility system that most authors found objective, merit-based, transparent, and equitable. Implementation of such a system should be considered for team science publications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.